TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10893361

Group type: EXPERIMENTAL
Intervention: Skin prick testing (SPT) for Aspergillus fumigatus (AF) as a screening tool and CT scan for diagnosis.
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: CT scan for diagnosis of ABPA.
Number of subjects: 255
Study: 8822241

Group type: EXPERIMENTAL
Intervention: 5‐min stroking protocol in addition to a perioral and intraoral stimulation program
Number of subjects: 18

Group type: COMPARATOR
Intervention: 5‐min stroking protocol (control group)
Number of subjects: 18
Study: 1464131

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 20
Study: 6322985

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (n = 15)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Self-regulated p.o. diet (control group; n = 16)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Response to therapy (both groups)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Initial state (both groups)
Number of subjects: 31
Study: 31396667

Group type: EXPERIMENTAL
Intervention: Deep convolutional neural network (CNN) with data augmentation, trained for 50 epochs, batch size of 8, learning rate of 0.0001, Adadelta optimizer, dropout of 0.20.
Number of subjects: 200
Study: 30611996

Group type: EXPERIMENTAL
Intervention: Lactoferrin (LF) administration for 3 months
Number of subjects: 0
Study: 28605043

Group type: EXPERIMENTAL
Intervention: Typical Angina (TA)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Nontypical Angina (NTA)
Number of subjects: 155
Study: 24976269

Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells (DCs) and IL-2
Number of subjects: 10
Study: 24411740

Group type: EXPERIMENTAL
Intervention: Immediate weight feedback
Number of subjects: 160

Group type: COMPARATOR
Intervention: Delayed weight feedback
Number of subjects: 160
Study: 22805422

Group type: EXPERIMENTAL
Intervention: Quercetin (QU) supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PL) supplementation
Number of subjects: 30
Study: 19238219

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP) treatment in symptomatic children
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP) treatment in asymptomatic infants
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Molecular markers examination for drug resistance
Number of subjects: 112
Study: 17321391

Group type: EXPERIMENTAL
Intervention: 1CU IOL
Number of subjects: 30

Group type: COMPARATOR
Intervention: AcrySof MA30 IOL
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both IOLs
Number of subjects: 30
Study: 15349013

Group type: EXPERIMENTAL
Intervention: Controlled-release paroxetine (CR)
Number of subjects: 3825

Group type: COMPARATOR
Intervention: Immediate-release paroxetine (IR)
Number of subjects: 3825
Study: 11696462

Group type: EXPERIMENTAL
Intervention: sCD40L concentration in cases (2.86 ng/mL)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: sCD40L concentration above 95th percentile (3.71 ng/mL)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Adjusted sCD40L concentration above 95th percentile
Number of subjects: 260
Study: 9559206

Group type: EXPERIMENTAL
Intervention: Four serological tests (Bio-Rad IgA, Bio-Rad IgG, Pyloriset EIA-A for IgA, Pyloriset EIA-G for IgG)
Number of subjects: 89
Study: 7870845

Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Apomorphine (0.5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (9 subjects)
Number of subjects: 20
Study: 2975951

Group type: EXPERIMENTAL
Intervention: High Dose Strategy (HDS) - interferon alpha‐N1 5M units m‐2 by continuous i.v. infusion over 24 h, escalating by 5 M units m‐2 day‐1 as tolerated over 10 days, repeated every 28 days.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Low Dose Strategy (LDS) - fixed dose of 2 M units m‐2 by intramuscular injection daily for 28 days, then daily for 7 days every other week.
Number of subjects: 53
Study: 31403361

Group type: EXPERIMENTAL
Intervention: Td vaccine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Colchicine and a single dose of Td vaccine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (colchicine and a single dose of vitamin B6)
Number of subjects: 66
Study: 28733130

Group type: EXPERIMENTAL
Intervention: Progressive exercise program (12-week postradiation)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Hypofractionation radiation
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Median grip strength of study participants
Number of subjects: 59
Study: 28498183

Group type: EXPERIMENTAL
Intervention: Facility-based peer support
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: Community-based peer support
Number of subjects: 1269

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 1269
Study: 26719545

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 103

Group type: COMPARATOR
Intervention: Regional anesthesia (vertical infraclavicular block)
Number of subjects: 103
Study: 23103783

Group type: EXPERIMENTAL
Intervention: 5% sodium chloride injection (pain condition)
Number of subjects: 13

Group type: COMPARATOR
Intervention: 0.9% sodium chloride injection (sham condition)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No injection (control condition)
Number of subjects: 13
Study: 21969643

Group type: EXPERIMENTAL
Intervention: Escitalopram plus placebo
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Bupropion sustained-release plus escitalopram
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended-release plus mirtazapine
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Measurement-based care
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 600
Study: 19820137

Group type: COMPARATOR
Intervention: Plasma levels of Bb and SC5b-9 on day of enrollment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Plasma levels of Bb and SC5b-9 on day 28 after discharge
Number of subjects: 17

Group type: COMPARATOR
Intervention: Correlation of circulating levels of complement pathway fragments with severity of renal injury
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Activation of the alternative pathway of complement
Number of subjects: 17
Study: 16849382

Group type: COMPARATOR
Intervention: Continuous infusion of ropivacaine 2 mg/ml with fentanyl 2 microg/ml at 10 ml/h
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hourly boluses of 10 ml of ropivacaine 2 mg/ml with fentanyl 2 microg/ml
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intermittent administration
Number of subjects: 40
Study: 14519623

Group type: EXPERIMENTAL
Intervention: 7.5 mg/m2/day rhAngiostatin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 15 mg/m2/day rhAngiostatin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 30 mg/m2/day rhAngiostatin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: rhAngiostatin treatment
Number of subjects: 24
Study: 10773178

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0
Study: 9085397

Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch plus brief physician counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief physician counseling alone
Number of subjects: 0
Study: 8449586

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg daily
Number of subjects: 0
Study: 2944997

Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Zomepirac 100 mg
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 31954680

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1905

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Repeat revascularization (after both PCI and CABG)
Number of subjects: 1905
Study: 31655834

Group type: EXPERIMENTAL
Intervention: 4mg intramuscular dexamethasone immediately after anesthesia
Number of subjects: 19

Group type: COMPARATOR
Intervention: 90mg etoricoxib 1 hour prior to the procedure
Number of subjects: 19
Study: 28822719

Group type: EXPERIMENTAL
Intervention: Thalidomide 200mg QD for 3 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no thalidomide)
Number of subjects: 30
Study: 26656025

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (U-TURN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care intervention
Number of subjects: 0
Study: 23188075

Group type: EXPERIMENTAL
Intervention: Naltrexone (0.1 mg/kg) orally for 8 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 20809092

Group type: EXPERIMENTAL
Intervention: Cost containment measures (12 of 16 interventions analyzed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost containment measures (4 effective interventions)
Number of subjects: 0
Study: 18840107

Group type: EXPERIMENTAL
Intervention: Gabapentin (800 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17175822

Group type: EXPERIMENTAL
Intervention: 3% mepivacaine at 20 degrees C
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3% mepivacaine at 4 degrees C
Number of subjects: 20
Study: 14638544

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d for 6 weeks (Group 1)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control subjects (Group 1)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control subjects (Group 2)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients in Group 2
Number of subjects: 46
Study: 10708469

Group type: EXPERIMENTAL
Intervention: Transesophageal 3-dimensional echocardiography (3DE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: M-mode echocardiography
Number of subjects: 20

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 20
Study: 8775119

Group type: EXPERIMENTAL
Intervention: Ice water‐filled CryoCuff
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Room temperature water in CryoCuff
Number of subjects: 71

Group type: COMPARATOR
Intervention: No CryoCuff
Number of subjects: 71
Study: 1486386

Group type: COMPARATOR
Intervention: Saline washout
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Suby G washout
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Solution R washout
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Returned acidic washout fluid
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Catheter encrustation
Number of subjects: 25
Study: 6721446

Group type: EXPERIMENTAL
Intervention: Baclofen (20 mg and 40 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30637839

Group type: EXPERIMENTAL
Intervention: TARGIT‐IORT
Number of subjects: 332

Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Pre-treatment group
Number of subjects: 332

Group type: COMPARATOR
Intervention: Post-treatment group
Number of subjects: 332
Study: 29265769

Group type: EXPERIMENTAL
Intervention: Sedentary time (measured objectively)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Sedentary time in inactive individuals (< 150 min/wk of MVPA)
Number of subjects: 124
Study: 26349047

Group type: EXPERIMENTAL
Intervention: Training with optimal load
Number of subjects: 21

Group type: COMPARATOR
Intervention: Training with load 10% below optimal load
Number of subjects: 21
Study: 25306897

Group type: EXPERIMENTAL
Intervention: Peer-teachers
Number of subjects: 198

Group type: COMPARATOR
Intervention: Clinicians
Number of subjects: 198

Group type: COMPARATOR
Intervention: Non-clinical staff
Number of subjects: 198
Study: 22429404

Group type: EXPERIMENTAL
Intervention: Standard care plus a self‐regulation based physical activity program (4‐STEPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 0
Study: 20082754

Group type: EXPERIMENTAL
Intervention: Yupingfeng Powder (10 days treatment)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Yupingfeng Powder
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 17418536

Group type: EXPERIMENTAL
Intervention: Mindfulness training with therapists practicing Zen meditation (MFG, n=58)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group without mindfulness training (CG, n=55)
Number of subjects: 196
Study: 16250192

Group type: EXPERIMENTAL
Intervention: ETMS use twice every weekday in 35‐min increments during an eight‐week period
Number of subjects: 12

Group type: COMPARATOR
Intervention: Home exercise programme
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ETMS/home exercise programme
Number of subjects: 12

Group type: COMPARATOR
Intervention: Home exercise programme followed by ETMS
Number of subjects: 12
Study: 12537632

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg twice a day for 3 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin B(1), B(6) and B(12) tablets
Number of subjects: 0
Study: 11493043

Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle intervention
Number of subjects: 535
Study: 9625319

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (1 g/day)
Number of subjects: 0
Study: 7932948

Group type: EXPERIMENTAL
Intervention: Electrostimulation of muscle (EMS) using a 'Complex-type' stimulator with flexible elastomer electrodes, current pulses of 200 microseconds at 70 Hz, contraction duration of 5 s, rest duration of 15 s, 10 min per session, three sessions per week for 4 weeks.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no EMS training)
Number of subjects: 12
Study: 2467117

Group type: EXPERIMENTAL
Intervention: Amlodipine (starting dose 2.5 mg, titrated to 5.0 mg and 10.0 mg at 2-week intervals)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol (starting dose 50 mg, titrated to 100 mg after 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29326129

Group type: EXPERIMENTAL
Intervention: Machine learning algorithm (random forest model)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Bundle branch block morphology and QRS duration
Number of subjects: 595
Study: 28069054

Group type: EXPERIMENTAL
Intervention: Multi-species probiotic
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 26156818

Group type: EXPERIMENTAL
Intervention: Brenner's Integrated Psychological Therapy (IPT) cognitive training, delivered once a week for 6 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 23870642

Group type: EXPERIMENTAL
Intervention: Intravenous iron substitution (ferric carboxymaltose)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study: 21632197

Group type: EXPERIMENTAL
Intervention: Web-based personalized feedback intervention (Check Your Drinking [CYD] screener)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 92
Study: 18378614

Group type: EXPERIMENTAL
Intervention: Myocardial Contrast Echocardiography (MCE)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Single-Photon Emission Computed Tomography (SPECT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: LBBB patients (group A)
Number of subjects: 63

Group type: COMPARATOR
Intervention: LBBB patients (group A) and left ventricular ejection fraction-matched control subjects (group B)
Number of subjects: 63
Study: 16616221

Group type: EXPERIMENTAL
Intervention: Replanting the inferior mesentery artery (IMA)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Ligation of the inferior mesentery artery (IMA)
Number of subjects: 160
Study: 12576167

Group type: COMPARATOR
Intervention: Levetiracetam with comedication not affecting drug metabolizing enzymes (gabapentin, lamotrigine, vigabatrin)
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Levetiracetam with enzyme‐inducing AEDs (carbamazepine, phenytoin, phenobarbital, primidone)
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Levetiracetam with valproic acid
Number of subjects: 590
Study: 11083353

Group type: EXPERIMENTAL
Intervention: Patients with RA
Number of subjects: 18

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 18
Study: 8803722

Group type: EXPERIMENTAL
Intervention: Nipradilol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 18
Study: 1617822

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30608606

Group type: EXPERIMENTAL
Intervention: Casein hydrolysate B
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intact caseinate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Casein hydrolysate A
Number of subjects: 20
Study: 29970168

Group type: EXPERIMENTAL
Intervention: Lifestyle‐Integrated Functional Exercise Program
Number of subjects: 0
Study: 27502103

Group type: EXPERIMENTAL
Intervention: Bosentan 2 mg/kg, given by nasogastric tube twice daily for ≥48 hours and up to 1 day after iNO weaning.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo, given by nasogastric tube twice daily for ≥48 hours and up to 1 day after iNO weaning.
Number of subjects: 21
Study: 24513129

Group type: EXPERIMENTAL
Intervention: Pre-shock pause <10s
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: Peri-shock pause <20s
Number of subjects: 2006

Group type: COMPARATOR
Intervention: Post-shock pause
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: Neurologically intact survival (Modified Rankin Score ≤ 3)
Number of subjects: 2006
Study: 23011561

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 64
Study: 20540635

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Atorvastatin and Probucol
Number of subjects: 31
Study: 17932160

Group type: EXPERIMENTAL
Intervention: Combined cardiac resynchronisation and implantable cardioverter defibrillator therapy
Number of subjects: 8307

Group type: COMPARATOR
Intervention: Implantable defibrillator therapy
Number of subjects: 8307

Group type: COMPARATOR
Intervention: Resynchronisation therapy alone
Number of subjects: 8307

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 8307
Study: 15531565

Group type: EXPERIMENTAL
Intervention: Hypoxia (breathing 12% O(2)) during 20-min 60 degrees head-upright tilt
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normoxia during 20-min 60 degrees head-upright tilt
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypoxia during 20-min 60 degrees head-upright tilt
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 16
Study: 12095068

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (ALA) in combination with photodynamic therapy (PDT)
Number of subjects: 0
Study: 10827645

Group type: EXPERIMENTAL
Intervention: Systematic clinical supervision
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nurses' view of the effects from clinical supervision
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Work-Related Strain Inventory (WRSI)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Satisfaction with Nursing Care and Work Questionnaire (SNCW)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sense of Coherence scale (SOC)
Number of subjects: 22
Study: 7824141

Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation at moderate stage of the disease in 6 subjects
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Neuropathologic changes typical of AD
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Genetic marker D14S43
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Presence of seizures
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Myoclonus and extrapyramidal signs
Number of subjects: 34
Study: 2337713

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 40
Study: 231737

Group type: EXPERIMENTAL
Intervention: Ketotifen for three months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31796029

Group type: EXPERIMENTAL
Intervention: Managerial and organizational transformation program for empowerment lasting 12 months
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 1000
Study: 28987643

Group type: EXPERIMENTAL
Intervention: High-load resistance training (HL) at 70% of one repetition maximum (1-RM)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low-load blood flow restricted (BFR) resistance training at 30% 1-RM with vascular restriction
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CON) performing light upper body resistance and flexibility training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All training groups (HL and BFR)
Number of subjects: 36
Study: 25056413

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling followed by repeated antimicrobial photodynamic therapy (PDT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Ultrasonic scaling (US) alone
Number of subjects: 27

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PDT
Number of subjects: 27
Study: 22573244

Group type: EXPERIMENTAL
Intervention: Active rinse containing zinc and chlorhexidine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Active rinse with adjunct tongue scraping
Number of subjects: 21

Group type: COMPARATOR
Intervention: Negative control rinse alone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control and tongue scraping sequence
Number of subjects: 21
Study: 21844095

Group type: EXPERIMENTAL
Intervention: State boredom
Number of subjects: 0
Study: 19655213

Group type: EXPERIMENTAL
Intervention: Pentax AWS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glidescope
Number of subjects: 0

Group type: COMPARATOR
Intervention: Macintosh
Number of subjects: 0
Study: 17366756

Group type: EXPERIMENTAL
Intervention: Interdental Brushes (IDB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dental Floss (DF)
Number of subjects: 10